These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15268635)

  • 1. Cephalosporins in clinical development.
    Page MG
    Expert Opin Investig Drugs; 2004 Aug; 13(8):973-85. PubMed ID: 15268635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging cephalosporins.
    Page MG
    Expert Opin Emerg Drugs; 2007 Nov; 12(4):511-24. PubMed ID: 17979596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possibility of drug design of beta-lactam antibiotics effective for multiresistant gram-positive pathogens].
    Okonogi K; Miyake A
    Nihon Rinsho; 1997 May; 55(5):1261-5. PubMed ID: 9155184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
    Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redesigning beta-lactams to combat resistance: summary and conclusions.
    Rossolini GM
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():30-3. PubMed ID: 17488374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer treatment options for skin and soft tissue infections.
    Raghavan M; Linden PK
    Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Dauner DG; Nelson RE; Taketa DC
    Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
    Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil: drug profile and clinical data.
    Kanafani ZA
    Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
    Garrison MW; Kawamura NM; Wen MM
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftobiprole medocaril: a new generation beta-lactam.
    Del Pozo JL; Patel R
    Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
    Casapao AM; Steed ME; Levine DP; Rybak MJ
    Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
    Anderson SD; Gums JG
    Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
    Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
    Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.